Get started
Work

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

Year: 2019
Type: article
Abstract: We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
DOI: 10.1186/s13045-019-0771-0
Authors: Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein, Justin Taylor
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,580
Funders: American Association for Cancer Research, Robert Wood Johnson Foundation, Conquer Cancer Foundation, American Society of Hematology, American Society of Clinical Oncology, National Institutes of Health, National Cancer Institute
Awards: G1743385758, G4102770861, G4252315074, G4263576196, Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic Malignancies, G5552471074, G9000003249, G9000230091, Cancer Center Support Grant
OpenAlex ID: W2969885248
FWCI: 1.207
Cites: 10
Cited by: 11
Related to: 10